Research status and progress of acute myeloid leukemia stem cells
10.3760/cma.j.cn341190-20210111-00052
- VernacularTitle:急性髓系白血病干细胞的研究现状和进展
- Author:
Jiahui LI
1
;
Zhenliang SUN
Author Information
1. 安徽理工大学附属奉贤医院中心实验室，上海 201499
- Keywords:
Leukemia,myeloid,acute;
Stem cells;
Hematopoietic stem cells;
Immunophenotyping;
Drug resistance,neoplasm;
Transcription factors;
Molecular targeted therapy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2022;29(9):1433-1436
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia is a clonal malignant proliferative disease of myeloid blasts of the hematopoietic system. The leukemia cell population is composed of cells of different stages. Acute myeloid leukemia stem cells are the cells that may cause diseases in immunodeficient animals and can regenerate themselves through continuous transplantation, which causes leukemia. Since more than 96% of leukemia stem cells are in the G0 stage, they may escape the effects of chemical drug stabbing, leading to drug resistance and recurrence of leukemia. Therefore, the key to the treatment of acute myeloid leukemia has always been how to remove leukemia stem cells without damaging hematopoietic stem cells. This review paper addresses the new developments in the immunophenotype of leukemia stem cells and leukemia stem cells-targeting therapy for acute myeloid leukemia.
